- Includes recent advancements from precision designed compounds -
- Functional personalised medicine platform unveiling unique adenosine biomarker to enrich for patients more likely to respond to. | April 19, 2023
Includes recent advancements from precision designed compounds Functional personalised medicine platform unveiling unique adenosine biomarker to enrich for patients more likely to respond to treatment
Repare Therapeutics (RPTX) Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Camonsertib PARPi combinations demonstrated 48% CBR in patients with unmet medical needs, across tumor types, and regardless of PARPi partner or platinum resistance, with a favorable safety and. | April 18, 2023
Majority of Best-selling Medicare Drugs Provide Limited Therapeutic Benefit miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.